About
No bio provided
This profile has not been completed yet.
Profile AI
Clement Penny is a biomedical researcher whose work centers on molecular oncology, translational cancer therapeutics, and nanomedicine. His scholarship integrates pharmacology, bioinformatics, and natural product research to advance targeted strategies against colorectal, prostate, and triple-negative breast cancers. He is widely recognized for exploring signaling pathways such as EGFR and MAPK and for investigating apoptosis regulation through BCL-2/BAX and p53 modulation.
His publications highlight innovative therapeutic approaches, including small-molecule inhibitors, phytochemical extracts from Southern African medicinal plants, and green-synthesized nanoparticles with anticancer potential. He has also contributed significantly to understanding treatment resistance and biomarker discovery in colorectal cancer, emphasizing translational relevance and pathway-driven interventions.
A notable strength of his research lies in exosome biology and long non-coding RNAs, particularly their roles in tumor progression, immune modulation, and RNA-based therapeutics. Through combined experimental and computational approaches, his work advances precision oncology and supports the development of novel, targeted cancer therapies.
Latest publications
Most recent scholarly works and contributions.